|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Each interquartile increment in walkability was associated with the lower blood pressure outcomes of DBP (β = -0.358, 95% CI: -0.42, -0.29 mmHg), SBP (β = -0.833, 95% CI: -0.95, -0.72 mmHg) as well as reduced hypertension risk (RR = 0.970, 95% CI: 0.96, 0.98).
|
29398408 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
In this cross-sectional study, 200 outpatients (161 women, 39 men) with essential HTN (systolic blood pressure [SBP] ≥ 140 mmHg and diastolic blood pressure [DBP] ≥ 90 mmHg) were recruited from August to November 2012.
|
28318434 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
In addition, short-term exposures to four (PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>2</sub>, NO<sub>2</sub>), two (PM<sub>2.5</sub> and SO<sub>2</sub>), and four air pollutants (PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>2</sub>, and NO<sub>2</sub>), were significantly associated with hypertension (ORs: 1.05-1.10), SBP (β values: 0.53-0.75 mmHg) and DBP (β values: 0.15-0.64 mmHg), respectively.
|
29331891 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
An increase of 0.1 in NDVI corresponded to a reduction in SBP of 1.39 mmHg (95% CI: 1.86, -0.93) and lower odds of hypertension (OR = 0.76, 95% CI: 0.69, 0.82).
|
31672364 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Stage 2 hypertension (SBP/DBP ≥ 140/90 mmHg) showed significant associations with cardiovascular disease and all-cause mortality, while elevated blood pressure (SBP 120-129 mmHg and DBP < 80 mmHg) showed null associations.
|
31288541 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Forty-one patients with and 82 patients without intradialytic hypertension (intradialytic SBP rise ≥10 mm Hg to > 150 mm Hg) matched in a 1: 2 ratio for age, sex, and hemodialysis vintage were included.
|
30347395 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Prespecified analyses of the Enhanced Control of Hypertension and Thrombolysis Stroke Study for patients enrolled in both arms: (i) low-dose (0.6 mg/kg body weight) or standard-dose (0.9 mg/kg) alteplase and (ii) intensive (target systolic BP [SBP] 130-140 mm Hg) or guideline-recommended (target SBP <180 mm Hg) BP management.
|
31812956 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
This randomized-cross-over study included 38 patients (age: 60.4 ± 11.1 years, male: 65.8%) with intradialytic hypertension (intradialytic-SBP increase ≥ 10 mmHg at ≥4 over 6 consecutive sessions).
|
30622317 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
The genetic risk score, calculated as the sum of BP-increasing alleles of FGF5-rs16998073, CYP17A1-rs11191548, CYP17A1-rs1004467 and MTHFR-rs17367504, was significantly associated with increased SBP (1.16 mmHg/allele, P = 9.01E-5), DBP (0.51 mmHg/allele, P = 4.40E-4) and hypertension risk (OR = 1.22/allele, P = 2.74E-7).
|
20852445 |
2011 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
MRI-derived subclinical HFF is associated with SBP and DBP as well as with hypertension in participants from the general population without history of cardiovascular disease.
|
28253218 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Distinguishing trajectories allows identification of subgroups at risk of hypertension and cardiovascular disease later in life and in addition can inform the design of targeted interventions to attenuate high SBP and DBP trajectories over time and maintain normal trajectories.
|
28234673 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
We used inverse variance weighting (IVW) to assess the relation of HbA1c with risk of hypertension (defined using the American College of Cardiology/American Heart Association 2017 guidelines), and SBP and DBP.
|
31386636 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
One-in-three antihypertensive medication users had stage 2 hypertension (SBP ≥160/DBP ≥100 mmHg).
|
28545582 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
In contrast, in inactive group, two polymorphisms and genetic risk score were significantly associated with SBP (rs17249754: β = 1.26, 95% confidence interval (CI) 0.61-1.90, p < 0.001; rs1004467: β = 0.68, 95%CI 0.03-1.32, p = 0.039; genetic risk score: β = 1.54, 95%CI 0.74-2.33, p < 0.001); three polymorphisms and genetic risk score were significantly associated with hypertension (rs17249754: odds ratio (OR) = 1.27, 95%CI 1.08-1.49, p = 0.004; rs1378942: OR = 1.25, 95%CI 1.00-1.57, p = 0.050 (marginally significant); rs16998073: OR = 1.17, 95%CI 1.01-1.37, p = 0.044; genetic risk score: OR = 1.38, 95%CI 1.13-1.68, p = 0.001).
|
23102448 |
2012 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Using data for 2,180 self-identified White, Black, Chinese, Japanese, and Hispanic participants from the Study of Women's Health Across the Nation, we examined associations among exposure to (higher vs. lower) everyday discrimination at baseline and BP and hypertension (HTN; systolic blood pressure [SBP] ≥ 140 mmHg; diastolic blood pressure [DBP] ≥ 90 mmHg; or self-reported HTN medication use) risk over a 10 year period.
|
30247506 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
This is a pilot randomized-cross-over study in 38 hemodialysis patients (age: 60.4 ± 11.1 years, men: 65.8%) with intradialytic hypertension (intradialytic SBP rise ≥10 mmHg at ≥4 over six consecutive sessions].
|
30063644 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
After stratifying the subjects according to blood pressure and blood glucose, the positive relationship between RHR and UACR remained in the subjects with normal blood pressure and normal glucose tolerance, while in the hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) group and the diabetic mellitus (FPG ≥ 7.0 mmol/L and/or PPG ≥ 11.1 mmol/L) group, the relationship disappeared.
|
31534974 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Newly defined stage 1 hypertension and elevated BP were associated with increased risk of incident CVD, whereas long-term changes of SBP and DBP had effects of varying degree on CVD incidence.
|
31116159 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
This exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study.
|
25695618 |
2015 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Inclusion criteria were age between 18 and 75 years, diagnosis of type 2 diabetes, poorly controlled hypertension over the last 12 months (mean clinic systolic blood pressure [SBP] ≥140 mm Hg and/or diastolic blood pressure [DBP] ≥90 mm Hg), access to a mobile phone, and ability to receive text messages and emails.
|
30964439 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
After Bonferroni correction the polymorphism rs4680 (ValMet) in COMT was significantly associated with lower SBP in participants treated with CCBs (P = .009) with an especially strong impact in elderly individuals (age ≥ 70) alone (Δ = -14.08 mm Hg, P = .0005).These results underline the important role of estrogens and catecholamines in hypertension and the importance of genotype dependent, age-related adjustments of calcium-channel blocker treatment.
|
28746172 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Patients with hypertension have a wide variation in BV parameters.BV does not correlate with SBP.
|
31463701 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Epidemiological studies reported an inconsistent association between stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) defined by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and cardiovascular disease (CVD) events.
|
31790053 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
This open-label, uncontrolled, observational study enrolled 30 patients (20 females and 10 males) with grade II-III uncontrolled arterial hypertension (SBP/DBP ≥ 160/100 mmHg) and no evidence of cerebrovascular disease.
|
30128642 |
2018 |